Meduloc Closes $4 Million Series B Financing Led by GenHenn Capital

Meduloc, an orthopedic medical device company based in West Chester, Pennsylvania, has successfully closed a $4 million Series B financing round. The funding was led by GenHenn Capital, with notable participation from Life Sciences Greenhouse Investments, Ben Franklin Technology Partners of Southeastern Pennsylvania, Broad Street Angels, and former Major League Baseball All-Star Andre Ethier. This financing round, announced on August 6, 2026, is aimed at supporting Meduloc's controlled alpha launch and the generation of clinical evidence for its innovative fracture fixation technology.

Meduloc specializes in the development of a flexible nitinol intramedullary fracture fixation platform, designed to provide stable fixation while preserving bone anatomy and avoiding joint violations in certain applications. The company’s FDA-cleared, sterile, single-use system is applicable across a variety of long-bone fracture scenarios in both adult and pediatric patients. The recent financing is expected to facilitate the establishment of commercial infrastructure and clinical experience necessary for broader adoption among orthopedic surgeons and patients.

The participation of prominent Pennsylvania investors underscores the strong support from the local investment community, particularly in the Greater Philadelphia region. The backing from organizations such as Life Sciences Greenhouse Investments and Ben Franklin Technology Partners highlights the growing interest in innovative medical technologies within the state. Meduloc's technology addresses significant needs in fracture care, presenting a differentiated solution that could enhance patient outcomes and recovery times.

As Meduloc prepares for its controlled alpha launch in August 2026, the company will collaborate with select orthopedic surgeons and institutions to gather clinical feedback and refine its offerings. This strategic approach will not only help in building clinical evidence but also in establishing relationships with key opinion leaders in the orthopedic field. The insights gained during this phase are expected to inform future commercial expansion and product enhancements.

The successful closing of this financing round reflects broader trends in the medical device sector, where innovation and investor confidence are increasingly aligned. With a growing emphasis on advanced treatment options that improve patient care, Meduloc's entry into the market comes at a time when the demand for effective fracture fixation solutions is on the rise. As the company moves forward with its commercialization efforts, it may set a precedent for future investments in the orthopedic medical device space, potentially attracting further attention from venture capitalists and strategic partners alike.